Decision Support Following Genetic Testing for Breast-Ovarian Cancer Susceptibility
- Conditions
- Ovarian CancerBreast Cancer
- Interventions
- Behavioral: Print DABehavioral: Inconclusive Results DABehavioral: Enhanced Print DABehavioral: Internet DABehavioral: Enhanced Internet DA
- Registration Number
- NCT02133703
- Lead Sponsor
- Georgetown University
- Brief Summary
This non-therapeutic trial is for women who have received results of genetic testing for BRCA1/2 mutations. The trial compares decision support tools designed to facilitate informed decision making regarding risk management following testing to usual care. The researchers will test separate decision support tools for women who receive positive test results and women who receive negative/inconclusive test results. Among women who receive a positive test result, an interactive decision support intervention will be compared to a print intervention. Among women who receive an inconclusive result, an interactive intervention will be compared to usual care.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 369
- Undergo BRCA1/2 genetic counseling and testing at one of four study sites
- Receive positive or uninformative test results
- English speaking
- Newly diagnosed breast cancer patients who have not yet initiated definitive breast cancer treatment
- Previous bilateral mastectomy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- FACTORIAL
- Arm && Interventions
Group Intervention Description Mutation Carrier: Print DA Print DA BRCA1/2 carriers randomized to this arm will receive a print decision aid without a preference clarification tool. Inconclusive Results: DA Inconclusive Results DA Participants who receive inconclusive results who are randomized to this arm will have access to an Internet decision tool designed to facilitate management decision making Mutation Carrier: Enhanced Print DA Enhanced Print DA BRCA1/2 carriers randomized to this arm will be sent a print-based decision aid with a print preference clarification tool. Mutation Carrier: Internet DA Internet DA BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support intervention without a preference clarification tool. Mutation Carrier: Enhanced Internet DA Enhanced Internet DA BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support including a preference clarification tool.
- Primary Outcome Measures
Name Time Method Decision Satisfaction 12-months post-randomization Satisfaction with Decision Scale
Psychological Distress 1-month post randomization Decision Conflict 1-month post-randomization Decisional Conflict Scale
Knowledge 1-month post randomization Knowledge of risk management options.
Health Related Quality of Life 12-months post randomization SF-12
Utilization of breast and ovarian cancer risk management options 12-months post-randomization We will assess uptake of the following risk management strategies:
1. Risk reducing surgery (mastectomy and oophorectomy)
2. Chemoprevention
3. Breast and ovarian cancer screening
- Secondary Outcome Measures
Name Time Method Knowledge 3-months post randomization Knowledge of risk management options
Psychological Distress 3-months post-randomization Decisional Conflict 3-months post-randomization Decisional Conflict Scale
Trial Locations
- Locations (1)
Georgetown University Medical Center/Lombardi Comprehensive Cancer Center
🇺🇸Washington, District of Columbia, United States